Clinical trial
Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors
NCT06638931 is registered in ClinicalTrials.gov with Instituto do Cancer do Estado de São Paulo as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Basket Study to Evaluate the Tissue-agnostic Efficacy of Anti-Programmed Cell Death Protein 1 (Anti-PD1) Monoclonal Antibody in Patients With Advanced Rare Tumors
- Lead sponsor
- Instituto do Cancer do Estado de São Paulo
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 16, 2024
- Completion date
- May 31, 2028
- Enrollment
- 28 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
adenoid cystic carcinoma, adrenal gland neoplasms, anal neoplasms, angiosarcoma, apocrine carcinoma, biliary tract neoplasms, cancer of unknown primary, carcinosarcoma, cholangiocarcinoma, clear cell endometrial cancer, fallopian tube neoplasms, fibrolamellar carcinoma, fibrosarcoma, gallbladder neoplasms, granulosa cell tumor, hemangioblastoma, hepatoblastoma, kaposi sarcoma, leiomyosarcoma, mesothelioma, metaplastic breast carcinoma, neuroblastoma, neuroendocrine tumors, neurofibrosarcoma, osteosarcoma, ovarian epithelial cancer, parathyroid carcinoma, penile neoplasms, primitive neuroectodermal tumor, secretory carcinoma of breast, sertoli-leydig cell tumor, small intestine neoplasms, soft tissue sarcoma, thyroid neoplasms, translocation renal cell carcinoma, trophoblastic tumor, urachal cancer, urethral neoplasms, vaginal neoplasms, vulvar neoplasms, yolk sac tumor